Abbott Laboratories $ABT Shares Sold by Dempze Nancy E

Dempze Nancy E reduced its holdings in Abbott Laboratories (NYSE:ABT) by 0.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 42,308 shares of the healthcare product maker’s stock after selling 354 shares during the period. Abbott Laboratories comprises approximately 3.3% of Dempze Nancy E’s holdings, making the stock its 7th biggest position. Dempze Nancy E’s holdings in Abbott Laboratories were worth $5,754,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories during the first quarter worth $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the first quarter worth $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories during the first quarter worth $30,000. JCIC Asset Management Inc. acquired a new stake in shares of Abbott Laboratories during the first quarter worth $32,000. Finally, Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories during the first quarter worth $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ABT has been the subject of several recent analyst reports. Mizuho increased their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Raymond James Financial decreased their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research report on Friday, July 18th. Royal Bank Of Canada increased their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Evercore ISI increased their target price on shares of Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and increased their target price for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $146.24.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $134.45 on Thursday. The firm has a 50-day moving average of $132.30 and a 200-day moving average of $131.48. The company has a market cap of $234.00 billion, a P/E ratio of 16.85, a P/E/G ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.